Skip to main content

Table 1 Clinical information from the primary and recurrent paired tumors

From: Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways

SAMPLE ID 1

SAMPLE ID 2

Gender

Age at diagnosis

Tumor Type

Cavernous Sinus Invation at 1 and 2 surgeries

Max Diameter (1st)

1st Volume (cm3)

1st PO Remanent

Treatment between tumors

Max Diameter (2nd)

2nd Volume

2nd PO Remanent

2nd Max Diameter (remanent)

Time between surgeries

NF-2006–006

NF-2009–012

Male

25

Gon

(+ / +)

35

42.87

YES

XRT

35

35.7

YES

27

1 year

NF-2007–020

NF-2010–012

Male

42

Gon

(+ / +)

23

9.89

YES

XRT

34

19.04

YES

24

3 years

NF-2007–029

NF-2009–019

Female

46

Gon

(+ / +)

30

15.87

YES

NO

23

9.2

YES

UNKNOWN

2 years

NF-2009–011

NF-2012–034

Female

63

Gon

(+ / +)

29

17.34

YES

NO

13

1.01

NO

7

1 year

NF-2009–026

NF-2010–056

Female

31

Gon

(+ / +)

27

16

YES

XRT

20

3.6

YES

21

1 year

AC-2010–010

AC-2011–005

Female

56

Soma

(-/ +)

NO MRI

-

NO MRI

NO

No MRI

-

YES

33

1 year

NF-2013–006

NF-2015–007

Male

20

Gon

(+ / +)

30

22.5

YES

NO

20

7.2

NO

14

2 years

CU-2013–005

CP-2021–001

Female

29

Met corth

(+ / +)

20

4.5

YES

XRT, TMZ, KETO, CABERG

18

4.6

YES

20

8 years

NF-2016–032

NF-2022–013

Female

39

Gon

(+ / +)

36

16.38

YES

NO

28

34.4

YES

35

5 years

NF-2018–018

NF-2022–046

Female

50

Sil corth

(+ / +)

33

24.94

YES

NO

36

37.9

YES

26

4 years

NF-2019–033

NF-2021–024

Female

66

Gon

(+ / +)

23

7.63

YES

LEVO

27

8.72

YES

27

2 years

  1. Tumor Type: Gon gonadotroph, Soma somatotroph, Met Corth metastatic corticotroph, Sil corth silent corticotroph
  2. PO post operative, XRT radiotherapy, TMZ temozolomide, KETO ketoconazole, CABERG cabergoline, LEVO levothyroxine